Only if someone is interested. These are the countries where Trobalt is available in Europe:
"The medicine is available as tablets in the following Member States: Austria, Belgium, Bulgaria, the Czech Republic, Denmark, Estonia, Finland, France, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom."
Source: http://www.ema.europa.eu/ema/index....news_detail_001802.jsp&mid=WC0b01ac058004d5c1
I'm on the AM101 trial but no movement in my T since 1st set of injections (19th - 21st Aug). It's the TACTT3 so placebo or real drug so no one knows. Will apply for Autifony when it opens but doubt i will be able to participate due to being on AM101. Retigabine would DQ me from AM101 so i would only be able to see if i can get it, not take it, if i went to a doctor. But i will try all the same.UK Peeps, please keep us updated re drug accessibility. Cheers!
That is who we want to be happy, so congratulations!my mother would say even 1000% transformation.
You can't, it's something that we need to put together and post as a separate post. We'll do it every once in a while, whenever there's a meaningful amount of data gathered. We'll see how it goes.@Markku how do we access the information on the forms?
I hope that the formality of filling out forms, however simple the form, doesn't dissuade a participant who would rather just casually update us with a post. I know I am lazy enough to when it comes to filling out forms. We should probably make it as easy as possible for participants to give us updates, and emphasize that the forms are optional.
Hmm, that list is from May 2013 taken from the news piece about restricting Retigabine to last-line treatment of partial epilepsy...We have a member in Iceland who cannot get his hands on Trobalt (?)
That list is inconclusive.
Don't know if this was posted, but I found this to be very informative:
http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2009.00111.x/full
How does stimulating mAChRs close M-channels?
It has been clear for some time that M-channel inhibition is a rather indirect response to mAChR stimulation (Figure 2), and that it was likely to be associated with the well-known effect of Gq activation, to stimulate phospholipase Cβ and catalyse the hydrolysis of membrane phosphatidylinositol-4,5-bisphosphate (PIP2) (Marrion, 1997). Earlier work concentrated (not surprisingly) on the actions of the products of this hydrolysis, inositol-1,4,5-trisphosphate (IP3) and diacylglycerol as potential 'diffusible messengers'. However, the more recent demonstration that – like many other membrane proteins – Kv7 (and native M) channels actually required PIP2 in order to enter the open state and close when membrane PIP2 levels are reduced or its polar head groups neutralized (Suh and Hille, 2002; Zhang et al., 2003; Robbins et al., 2006; Suh et al., 2006) has led to a complete volte-face – namely, that closure results, not from the accumulation of hydrolysis products but instead from the reduction in membrane PIP2 levels that results from its hydrolysis. Perhaps the most convincing evidence for this is that mAChR-induced inhibition of both expressed Kv7.2/7.3 channels and native neuronal M-channels is actually reduced or prevented when membrane PIP2 levels are increased by over-expressing the PI5-kinase (Winks et al., 2005; Suh et al., 2006), rather than increased as would be anticipated were closure to depend on hydrolysis products. This in turn has highlighted the very large and rapid changes in membrane PIP2 levels following mAChR stimulation, the concentration apparently falling by 90% plus within a few seconds (Winks et al., 2005; Suh et al., 2004; see also Willars et al., 1998). Direct evidence for this rapid depletion has recently been obtained by using a fluorescent probe that binds to PIP2 in the membrane then moves into the cytosol as PIP2 levels fall (Hughes et al., 2007; Quinn et al., 2008). The primary PIP2-binding site in the Kv7.2/7.3 channel has recently been identified as a cluster of basic amino acids in the carboxy-terminus (Hernandez et al., 2008): homology screening suggests that this region forms an interaction site with membrane lipids similar to that formed by Kir channels, which are also activated by PIP2 (see Logothetis et al., 2007).
Doesn't appear to be selective enough. To be more effective and less side-effect prone than retigabine, the drug would have to target Kv7.4 exclusively (and maybe Kv7.1, though how it'd do that without affecting the heart is an open question). Opening Kv channels in general, or even just Kv7 channels would have effects we don't want. Now if there's an enzyme that acts only on Kv7.4, that's a path worth exploring.To summarize (according to how I understood it) - the molecular mechanism of why Kv7 channels close in the first place, is thought to be caused to the decreased levels of the PIP2 (a phospholipid component of the membrane). When they increased those levels by over-expressing PI5-kinase (an enzyme), the Kv channel inhibition was reduced or prevented. (see bolded text above).
If so, can something (a drug, etc.) that overexpresses PI5-kinase help open up the Kv7 channels? Could this be another approach?
Thank you I am utterly terrified now thanks to that wiki photo. Maybe it's a reality check I need.Interesting clinical trial. Thank you for reporting it.
I just found this April, 2012, pdf on urinary retention and tinnitus--the actual numbers during the clinical trials. Everyone interested in the drug should read it. While rare (2%) and reversible, urinary retention is serious. Other kidney problems, notably Hydronephrosis, is also serious and occurred in two people participating in Retigabine's clinical trials.
I might get Trobalt tomorrow if everything works out.
Wish me luck.
Thanks Johno for the update. It sounds like something IS happening to your T and heading in the right direction. Good luck with getting a new supply of meds and staying on course getting the 200mg supply.Report:
Hello . I was on 3x50 entry dosage from 26 august to 2 september.(From 3 september i am at 100mg dosage)
My report: 50mg dosage is nearly ineffective, except central T and hissing. Central T is quieter 30%-50% and hissing is still here, but it is more soft and less intrusive. Tonal side Tinnituses are without changes. Effects are most noticeable three hours after pill swallowing, after another 2 hours it slowly fades away.
I had one side effect - mild bladder pressure, feels like bladder cold, but for now its nearly disappeared - body needs some time to adapt retigabine chemistry. 50mg dosage is good for this adaption - possible side effects are much more tolerable (now with 2nd day with 100mg dosage, bladder issue is not worsening) . No problems with urinating.
I have only one pack of Trobalt, 84x100mg, i hope i will be able to get another(200mg), because doctor is on 3-week vacation from sept. (she had wedding last weekend).
If not, experiment will have to be interrupted.
Ah, how long that is good question maybe 4-5 weeks on 200 mg.
I will be going to my gp next week to see if he will give me a prescription of this stuff I have had tinnitus for almost 3 month so I'm still In the acute stages idk how I got my T I had surgery and got my gall bladder removed took OxyContin for 3 days for the pain and on the third day I was just sitting watching tv around 12:00 pm I started to hear my left ear ring for no reason it sucks only my left ear rings and since it's been about 2 months and 27 days it's pretty much in my head now I have a thread if u want to read it i do have tmj will I think I do doc keep telling me a lot of people have clicking in there jaw and they just live with it so I have not got a MRI scan on my jaw yet thought it was my teeth so I got 3 wisdom teeth pulled 2 on left side and 1 on right had a dead tooth extracted also dentist told me it might be that but been a week and no deffrence in my tinnitus ummmm but yea if u want to hear my whole story u can Goto my thread but I will be getting this drug next Week should be easy since I live in the United States and I have access I'll keep u guys updated after I get it
In summary, going up slow in dosage is number one. (As mostly reported from our testers experience too).
Then stopping immediately if retention really gets going, rather than just some initial twinges of discomfort or slight slowing of urine stream, which could almost be expected.
Thanks for your response. This is definitely not acute UR . I can pee. I'd just say if i notice it my stream is at 85-90% power as opposed 100% percent. The effects certainly have not got any worse but if they don't subside I'm going to talk to my GP or talk to a neurologist who knows the med and my most likely will stop taking it daily .(What the hell is a + Multi-quote????? Yeah, yeah, me and my "Quoting war").
Hey @SoulStation ...the "meteorited" kidney pic there was what I regard to be a pretty extreme example of 'overdose proportions'. In fact I have great wonder that the subject of such could have been alive with stuff pouring out of holes that big...Uh, maybe the specimen was from an autopsy. All you wanted to hear. Ha, ha...
But seriously, urinary retention should not be sniffed at:
"Urinary retention is the inability to empty the bladder completely. Urinary retention can be acute or chronic. Acute urinary retention happens suddenly and lasts only a short time. People with acute urinary retention cannot urinate at all, even though they have a full bladder. Acute urinary retention, a potentially life-threatening medical condition, requires immediate emergency treatment. Acute urinary retention can cause great discomfort or pain."
I had dinner with one of my doc friends last night and asked him what to do if it developed while I was on Potiga...His reply was "see your neighbour" (a specialist urologist). Also that there are drugs that relax the muscles involved, but without even looking I can guess they may affect the same K channels that are causing it...or at least add more complex "what the hell do we do now ring-around-the-roses" issues for the poor neurons up in brain-land dealing with all this.
In summary, going up slow in dosage is number one. (As mostly reported from our testers experience too).
Then stopping immediately if retention really gets going, rather than just some initial twinges of discomfort or slight slowing of urine stream, which could almost be expected.
As a total aside....DO WE HAVE ANY WOMEN INTENDING TO TRY RETIGABINE??? Is this just a guy thing going on here??? Would be nice to get a more balanced gender perspective as there may be subtle differences in reactions, etc., etc., etc.
Thanks... Zimichael
The effects certainly have not got any worse but if they don't subside I'm going to talk to my GP or talk to a neurologist who knows the med and my most likely will stop taking it daily